J.B. Chemicals & Pharmaceuticals Limited has announced the availability of its Q3FY26 earnings call recording, providing investors and analysts with access to management discussions on the company's third quarter performance and developments.

Earnings Call Disclosure

The company has made the audio recording of its conference call available on its official website, following the investor and analyst session held on January 19, 2026 at 1:30 PM IST. The call focused on results and developments for the third quarter ended December 31, 2025.

Regulatory Compliance

The disclosure has been made pursuant to Regulation 30 read with Schedule III and Regulation 46(2)(oa) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory framework mandates companies to make such investor communications publicly accessible.

Previous Performance Context

The company had previously demonstrated resilient performance with sustained sales momentum despite challenging year-over-year comparisons. Management had expressed optimism about maintaining positive sales momentum, indicating confidence in the company's operational performance and market positioning in the pharmaceutical sector.

Access Information

Investors and analysts can access the Q3FY26 earnings call recording through the dedicated link provided on the company's website. The communication was formally disclosed to BSE Limited under the company's scrip code 506943 and stock symbol JBCHEPHARM, ensuring transparency and regulatory compliance for all stakeholders.

J.B. Chemicals & Pharmaceuticals Limited announced robust financial results for Q3FY26, demonstrating strong operational performance across all business segments. The pharmaceutical company reported significant growth in revenue, profitability, and margins, reinforcing its position as one of the fastest-growing pharmaceutical companies in India.

Strong Revenue Performance Across All Segments

The company delivered impressive revenue growth during the quarter under review. Consolidated revenue from operations reached ₹990.00 crores in Q3FY26, marking a 10% increase compared to ₹900.00 crores recorded in Q3FY25. The domestic formulations business continues to be a key growth driver, maintaining its outperformance against the Indian pharmaceutical market with sustained momentum across key therapeutic areas.

Exceptional Profitability Growth and Strong Bottom Line

The company's profitability metrics demonstrated strong momentum during the quarter. Consolidated net profit after tax increased 15% to ₹179.00 crores in Q3FY26, compared to ₹156.00 crores in Q3FY25. This robust profit growth reflects the company's effective operational strategies and strong execution across business segments.

Enhanced EBITDA Performance and Margin Expansion

The company showcased improved operational efficiency with strong EBITDA performance during the quarter. EBITDA reached ₹270.00 crores in Q3FY26, representing a significant increase from ₹245.00 crores in the corresponding quarter of the previous year. The EBITDA margin expanded to 27.20% in Q3FY26, compared to 26.86% in Q3FY25, demonstrating the company's ability to enhance operational leverage and cost optimization.

Domestic Business Maintains Strong Growth Trajectory

The domestic formulations business showcased robust performance with key flagship brands delivering strong growth during the quarter. The company's established brand portfolio across key chronic therapies continued to demonstrate resilience and market share gains. Key brands such as Cilacar, Cilacar-T, Nicardia and Sporlac maintained their growth momentum, contributing to the overall domestic business performance.

International Operations Show Sustained Performance

The international business segment maintained its positive trajectory with continued growth across several key markets including South Africa, Russia, USA and branded export markets. The CDMO business sustained its growth momentum, contributing to the overall international revenue performance. The company's diversified geographical presence continues to provide stability and growth opportunities.

Strategic Outlook and Management Focus

With strong financial performance and robust operational metrics, the company remains well-positioned for sustained growth. The management continues to focus on strengthening flagship brand franchises, expanding market presence, and scaling CDMO businesses. The company's strong balance sheet and sustained cash flow generation provide a solid foundation for future growth initiatives and strategic investments.